showed that preexisting Trm cells, marked by high cytotoxic potential and ZNF683 expression, are associated with favorable responses to neoadjuvant anti‐PD‐1 therapy in head and neck cancer.[94] Additionally, Virassamy et al. This evidence concerns the gene PDCD1 and head and neck cancer.